AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events
Phase 3
Terminated
- Conditions
- Elevated High-sensitivity C-Reactive Protein (hsCRP)
- Interventions
- Other: Placebo
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2014-03-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 17802
- Registration Number
- NCT00239681
- Locations
- 🇻🇪
Research Site, Punto Fijo, Estado Falcon, Venezuela
Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 160
- Registration Number
- NCT00239343
- Locations
- 🇸🇪
Research Site, Lund, Sweden
🇩🇰Research Stie, Herlev, Denmark
Budesonide / Formoterol in Treatment of Exacerbations of COPD
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00239278
- Locations
- 🇳🇱
Research Site, Groningen, Netherlands
Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy
Phase 3
Completed
- Conditions
- Hypercholesteremia
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 824
- Registration Number
- NCT00239330
- Locations
- 🇧🇪
Research Site, Sint-Agatha-Berchem, Belgium
Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer
Phase 1
Completed
- Conditions
- Non-Metastatic Prostate Cancer
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT00239291
- Locations
- 🇫🇮
Research site, Helsinki, Finland
Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer
Phase 1
Completed
- Conditions
- Head and Neck Neoplasms
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00239304
- Locations
- 🇫🇮
Research Centre, Helsinki, Finland
A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme
Phase 2
Completed
- Conditions
- Glioblastoma
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00238797
- Locations
- 🇸🇪
Research Site, Umeå, Sweden
SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2008-01-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1300
- Registration Number
- NCT00238784
- Locations
- 🇨🇦
Research Site, Brampton, Ontario, Canada
Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer
Phase 1
Terminated
- Conditions
- Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 34
- Registration Number
- NCT00237900
- Locations
- 🇫🇮
Reseach Site, Helsinki, Finland
Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00235911
- Locations
- 🇳🇱
Research Site, Groningen, Netherlands
© Copyright 2025. All Rights Reserved by MedPath